Journal of the European Academy of Dermatology and Venereology

Papers
(The H4-Index of Journal of the European Academy of Dermatology and Venereology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Editor's Picks261
Pioneers in Dermatology and Venereology: an Interview with Professor David M. Pariser179
Clinical evaluation of anaesthetic‐like effect of two dermocosmetic formulations containing Aquaphilus dolomiae extract‐G3 in subjects with sensitive facial skin170
Pioneers in Dermatology and Venereology: An Interview with Professor Danilo V. Stevanovic159
Pioneers in Dermatology and Venereology: An Interview with Professor An Goossens150
Are non‐fungible tokens the barrier to realizing the Dermoverse?133
Announcement113
84
Announcement78
Editor's Picks January 202477
Commentary on vitiligo patient population and disease burden in France: VIOLIN Study results from the CONSTANCES cohort73
Announcement70
Issue Information67
Peer review, scientific publishing and the law of reciprocity66
66
Pioneers in Dermatology and Venereology: an interview with Professor Sarolta Kárpáti64
Chat GPT in dermatology: Progressive or problematic?62
Efficacy of imiquimod in the management of lentigo maligna58
Flagellate purpura associated with COVID‐19 vaccination57
A dermocosmetic product containing the sap of oat plantlets and Garcinia mangostana extract improves the clinical signs of acne57
2013–2023: A decade of progress and challenges in dermatology as reflected in JEADV57
Louis Adolphus Duhring: An enduring legacy54
Real‐world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single‐centre, prospective, open‐label study50
Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab49
Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice49
Dupilumab for the treatment of refractory allergic contact dermatitis from rubber/latex concomitant with atopic dermatitis49
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study48
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma47
Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 202446
Issue Information44
Contact allergy may enhance further sensitization to new chemicals, but individual susceptibility traits are important for polysensitization43
Announcement43
43
Dalbavancin for the treatment of severe hidradenitis suppurativa42
Announcement42
The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use42
A case of eruptive halo nevi following COVID‐1940
Pityriasis lichenoides et varioliformis acuta after SARS‐CoV‐2 infection and relapse after vaccination40
The chicken or the egg of lymphopenia in atopic eczema39
Genomic and antimicrobial resistance analyses of Neisseria gonorrhoeae isolates, Burkina Faso, 2018–201939
Erythema multiforme major associated with molnupiravir treatment for SARS‐CoV‐2 infection: First report39
0.052103996276855